Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1985 1
1986 1
1987 4
1988 3
1989 5
1990 1
2015 2
2016 2
2017 1
2018 1
2019 4
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Renoprotective Effects of DPP-4 Inhibitors.
Kawanami D, Takashi Y, Takahashi H, Motonaga R, Tanabe M. Kawanami D, et al. Among authors: motonaga r. Antioxidants (Basel). 2021 Feb 5;10(2):246. doi: 10.3390/antiox10020246. Antioxidants (Basel). 2021. PMID: 33562528 Free PMC article. Review.
Traumatic lung pseudocyst.
Shirakusa T, Araki Y, Tsutsui M, Motonaga R, Iwanaga M, Ogami H, Matsuba K. Shirakusa T, et al. Among authors: motonaga r. Thorax. 1987 Jul;42(7):516-9. doi: 10.1136/thx.42.7.516. Thorax. 1987. PMID: 3438895 Free PMC article.
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, Horikawa T, Fujimura-Tanaka Y, Hamanoue N, Motonaga R, Tanabe M, Inoue R, Yanase T, Kawanami D. Komatsu S, et al. Among authors: motonaga r. Endocr J. 2020 Jan 28;67(1):99-106. doi: 10.1507/endocrj.EJ19-0428. Epub 2019 Nov 27. Endocr J. 2020. PMID: 31776304 Free article.
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Tsutsumi Y, Nomiyama T, Kawanami T, Hamaguchi Y, Terawaki Y, Tanaka T, Murase K, Motonaga R, Tanabe M, Yanase T. Tsutsumi Y, et al. Among authors: motonaga r. PLoS One. 2015 Oct 6;10(10):e0139709. doi: 10.1371/journal.pone.0139709. eCollection 2015. PLoS One. 2015. PMID: 26439622 Free PMC article.
Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T, Nomiyama T, Kawanami T, Hamaguchi Y, Horikawa T, Tanaka T, Irie S, Motonaga R, Hamanoue N, Tanabe M, Nabeshima K, Tanaka M, Yanase T, Kawanami D. Shigeoka T, et al. Among authors: motonaga r. J Diabetes Investig. 2020 Sep;11(5):1137-1149. doi: 10.1111/jdi.13247. Epub 2020 Apr 9. J Diabetes Investig. 2020. PMID: 32146725 Free PMC article.
High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan.
Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, Yoneda T, Kurihara I, Itoh H, Katabami T, Ichijo T, Wada N, Shibayama Y, Yoshimoto T, Ashida K, Ogawa Y, Kawashima J, Sone M, Inagaki N, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Hashimoto S, Yamada M, Yoshikawa Y, Kai T, Suzuki T, Kawamura T, Naruse M; Japan Primary Aldosteronism Study Group. Akehi Y, et al. Among authors: motonaga r. Diabetes Care. 2019 May;42(5):938-945. doi: 10.2337/dc18-1293. Diabetes Care. 2019. PMID: 31010944
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D; Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial. Terawaki Y, et al. Among authors: motonaga r. Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802709 Free PMC article.
Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice.
Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T. Takahashi H, et al. Among authors: motonaga r. Biochem Biophys Rep. 2019 Apr 19;18:100640. doi: 10.1016/j.bbrep.2019.100640. eCollection 2019 Jul. Biochem Biophys Rep. 2019. PMID: 31032431 Free PMC article.
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T; Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial. Nomiyama T, et al. Among authors: motonaga r. Endocr J. 2018 Aug 27;65(8):859-867. doi: 10.1507/endocrj.EJ18-0022. Epub 2018 May 26. Endocr J. 2018. PMID: 29806620 Free article. Clinical Trial.
29 results